Sanofi and Regeneron study shows efficacy of severe asthma therapy

Sanofi and Regeneron have announced clinical study data showing the effectiveness of a new investigational treatment for severe asthma.

Data from a phase III study has shown that the biologic therapy dupilumab, when provided to adults and adolescents with severe, steroid-dependent asthma, was able to meet its primary endpoint and key secondary endpoints.

When added to standard therapies, dupilumab significantly reduced the use of maintenance oral corticosteroids by 70 percent on average, compared to 42 percent with placebo, over 24 weeks of treatment.

The treatment was also able to reduce asthma attacks and improve lung function across a broad population of uncontrolled asthma patients.

Dr Elias Zerhouni, president of global research and development at Sanofi, said: "It is striking that dupilumab showed a consistent improvement in lung function across the pivotal asthma programme, as this is critically important for patients with severe asthma struggling with declines in their everyday breathing ability."

This was the first study with a biologic to show benefits in a severe steroid-dependent asthma population that enrolled patients regardless of blood eosinophil levels, or any other type 2 biomarkers at baseline.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.